Gigantism and Acromegaly Differential Diagnoses
- Author: Alicia Diaz-Thomas, MD, MPH; Chief Editor: Stephen Kemp, MD, PhD more...
Differentials in gigantism include the following:
- Familial tall stature
- Exogenous obesity
- Cerebral gigantism (Sotos syndrome): From NSD1 gene mutation or other causes
- Weaver syndrome
- Estrogen receptor mutation
Carney complex is a familial multiple neoplasia and lentiginosis syndrome. Growth hormone (GH) ̶ producing pituitary tumors have been described in individuals with the disorder.
Carney complex can exist in the following forms:
- Carney complex (NAME syndrome [nevi, atrial myxoma, myxoid neurofibroma, ephelides])
- Carney complex (LAMB syndrome [lentigines, atrial myxoma, mucocutaneous myxomas, blue nevi])
Manifestations and primary findings in Carney complex include cardiocutaneous syndrome, which is characterized by the following:
- Pigmented skin lesions and atrial myxomas
- Lentigines (mucocutaneous)
- Atrial myxomas (may be fatal)
- Mucocutaneous myxomas
- Blue nevi
- Congenital melanocytic nevi
Endocrine abnormalities of Carney complex include the following:
- Endocrine overactivity
- Cushing syndrome
- Sexual precocity in boys
- Thyroid hyperplasia
- Primary pigmented nodular adrenocortical disease
- Testicular tumors
- Uterine myxomas
McCune-Albright syndrome is manifested clinically by the presence of the following:
- Polyostotic fibrous dysplasia of bone
- Hyperpigmented skin macules
- Precocious sexual development in children
- Cushing syndrome
- Sexual precocity
- Hypophosphatemic hyperphosphaturic rickets
Pseudoacromegaly is defined as the presence of acromegaloid features in the absence of elevated levels of GH or insulinlike growth factor I (IGF-I) in patients with severe insulin resistance.
Pachydermoperiostosis syndrome is manifested clinically by finger clubbing, extremity enlargement, hypertrophic skin changes, and periosteal bone formation.
Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010 Aug. 95(8):3648-56. [Medline].
Nainggolan L. Gene Discovery in Giants Could Shed Light on Human Growth. Medscape Medical News. Available at http://www.medscape.com/viewarticle/836216.. Accessed: December 12, 2014.
Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014 Dec 18. 371(25):2363-74. [Medline].
Al-Bedaia M, Al-Khenaizan AS. Acromegaly presenting as cutis verticis gyrata. Int J Dermatol. 2008 Feb. 47(2):164. [Medline].
Bush ZM, Vance ML. Management of acromegaly: is there a role for primary medical therapy?. Rev Endocr Metab Disord. 2008 Mar. 9(1):83-94. [Medline].
Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006 Jun. 91(6):2112-8. [Medline].
Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010 Jul. 95(7):3141-8. [Medline].
Colak Ozbey N, Kapran Y, Bozbora A, Erbil Y, Tascioglu C, Asa SL. Ectopic growth hormone-releasing hormone secretion by a neuroendocrine tumor causing acromegaly: long-term follow-up results. Endocr Pathol. 2009 Summer. 20(2):127-32. [Medline].
Uchoa HB, Lima GA, Corrêa LL, Vidal AP, Cavallieri SA, Vaisman M, et al. Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. Arq Bras Endocrinol Metabol. 2013 Dec. 57(9):685-90. [Medline].
Soares BS, Eguchi K, Frohman LA. Tumor deletion mapping on chromosome 11q13 in eight families with isolated familial somatotropinoma and in 15 sporadic somatotropinomas. J Clin Endocrinol Metab. 2005 Dec. 90(12):6580-7. [Medline].
Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013 Sep. 16(3):294-302. [Medline]. [Full Text].
Oshino S, Nishino A, Suzuki T, et al. Prevalence of cerebral aneurysm in patients with acromegaly. Pituitary. 2013 Jun. 16(2):195-201. [Medline].
Stelmachowska-Banas M, Zdunowski P, Zgliczynski W. Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms?. Endokrynol Pol. 2009 Jan-Feb. 60(1):20-4. [Medline].
Dworakowska D, Gueorguiev M, Kelly P, Monson JP, Besser GM, Chew SL, et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J Endocrinol. 2010 Jul. 163(1):21-8. [Medline].
Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord. 2008 Mar. 9(1):41-58. [Medline].
Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J. 2008 Mar. 55(1):67-71. [Medline].
Izzard AS, Emerson M, Prehar S, Neyses L, Trainer P, List EO, et al. The cardiovascular phenotype of a mouse model of acromegaly. Growth Horm IGF Res. 2009 Oct. 19(5):413-9. [Medline].
[Guideline] Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly--2011 update: executive summary. Endocr Pract. 2011 Jul-Aug. 17(4):636-46. [Medline].
Wang M, Mou C, Jiang M, Han L, Fan S, Huan C, et al. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol. 2012 May. 166(5):797-802. [Medline].
Almalki MH, Chesover AD, Johnson MD, Wilkins GE, Maguire JA, Ur E. Characterization of management and outcomes of patients with acromegaly in Vancouver over 30 years. Clin Invest Med. 2012 Feb 1. 35(1):E27-33. [Medline].
Sata A, Ho KK. Growth hormone measurements in the diagnosis and monitoring of acromegaly. Pituitary. 2007. 10(2):165-72. [Medline].
Daroszewski J, Bolanowski M, Kaluzny M, Siewinski M. The imbalance of cathepsin B-like activity in acromegalic patients--preliminary report. Neuro Endocrinol Lett. 2010. 31(2):256-60. [Medline].
Roelfsema F, Biermasz NR, Romijn JA, Pereira AM. Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov. 10(4):875-90. [Medline].
[Guideline] Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014 Nov. 99(11):3933-51. [Medline].
[Guideline] Nainggolan L. New Guidelines for Acromegaly Include Advice on Pregnancy. Medscape Medical News. Nov 10 2014. [Full Text].
Azkur D, Yoldas T, Toyran M, Kocabas CN. A pediatric case of anaphylaxis due to octreotide. Asian Pac J Allergy Immunol. 2011 Dec. 29(4):361-3. [Medline].
Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, Chihara K. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J. 2013. 60(5):651-63. [Medline].
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 2014 Aug 8. [Medline].
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Nov. 2(11):875-84. [Medline].
Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011 May. 96(5):1327-35. [Medline].
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012 May. 97(5):1589-97. [Medline].
Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012 Apr. 97(4):1187-93. [Medline].
Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol. 2005 Aug. 153(2):195-201. [Medline].
Castinetti F, Morange I, Dufour H, Regis J, Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary. 2009. 12(1):3-10. [Medline].
Weber DC, Momjian S, Pralong FP, Meyer P, Villemure JG, Pica A. Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma. Radiat Oncol. 2011 Dec 8. 6:169. [Medline]. [Full Text].
Jagannathan J, Yen CP, Pouratian N, Laws ER, Sheehan JP. Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife. J Neurooncol. 2009 May. 92(3):345-56. [Medline].
Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, et al. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf). 2006 Mar. 64(3):245-9. [Medline].
Abe T, Tara LA, Lüdecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery. 1999 Jul. 45(1):1-10. [Medline].
Ronchi CL, Giavoli C, Ferrante E, Verrua E, Bergamaschi S, Ferrari DI, et al. Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments. Eur J Endocrinol. 2009 Jul. 161(1):37-42. [Medline].
van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res. 2006 Apr. 16(2):101-7. [Medline].
Chahal HS, Stals K, Unterländer M, Balding DJ, Thomas MG, Kumar AV, et al. AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med. 2011 Jan 6. 364(1):43-50. [Medline].
Kannan S, Kennedy L. Diagnosis of acromegaly: state of the art. Expert Opin Med Diagn. 2013 Sep. 7(5):443-53. [Medline].